<?xml version="1.0" encoding="UTF-8"?>
<p>Next, we tested the prophylactic (pre-treatment) (
 <xref ref-type="fig" rid="viruses-12-01041-f005">Figure 5</xref> and 
 <xref rid="viruses-12-01041-t002" ref-type="table">Table 2</xref>) and co-treatment inhibitory (
 <xref ref-type="fig" rid="viruses-12-01041-f006">Figure 6</xref> and 
 <xref rid="viruses-12-01041-t003" ref-type="table">Table 3</xref>) activity of the ten compounds against ZIKV Paraiba/2015, maximal effective concentrations were also evaluated (
 <xref ref-type="app" rid="app1-viruses-12-01041">Table S1</xref>). Potent prophylactic antiviral activity was observed for Mycophenolate mofetil, Mycophenolic acid, and AVN-944 based on SI-MTT values, whereas all other compounds were moderate to weak inhibitors (
 <xref ref-type="fig" rid="viruses-12-01041-f005">Figure 5</xref> and 
 <xref rid="viruses-12-01041-t002" ref-type="table">Table 2</xref>). Based on SI-XTT values, OSU-03012 had the highest potent prophylactic antiviral activity, and Pyrazofurin, Azauridine, Azaribine, Obatoclax, and Brequinar demonstrated the weakest prophylactic antiviral activity (
 <xref ref-type="fig" rid="viruses-12-01041-f005">Figure 5</xref> and 
 <xref rid="viruses-12-01041-t002" ref-type="table">Table 2</xref>). ATA, included as a control, exhibited potent and moderate prophylactic inhibitor based on the SI-MTT and SI-XTT values, respectively (
 <xref ref-type="fig" rid="viruses-12-01041-f005">Figure 5</xref> and 
 <xref rid="viruses-12-01041-t002" ref-type="table">Table 2</xref>). In pre-treatment conditions, Mycophenolate mofetil, Mycophenolic acid, and AVN-944 exhibited potent antiviral activity against ZIKV based on SI-MTT and OSU-03012 exhibited potent antiviral activity based on SI-XTT.
</p>
